Akèy › Kansè renn (Kasinom selil renn) › North Carolina › Durham
Etid klinik pou Kansè renn (Kasinom selil renn) nan Durham, NC
12 etid pou Kansè renn (Kasinom selil renn) ap chèche patisipan nan sit nan ak bò kote Durham (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)
Ap rekriteFaz 1/2
- Duke Cancer Institute ( Site 5015), Durham
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- Durham VA Medical Center, Durham
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Ap rekriteFaz 1
- Exelixis Clinical Site #12, Durham
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Ap rekriteFaz 2
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi lwen
DESTINY-PANTUMOUR04
Ap rekriteEtid obsèvasyon
- Research Site, Durham
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
Ap rekriteFaz 2
- Duke University Medical Center, Durham
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi lwen
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Ap rekriteEtid obsèvasyon
- UNC- Chapel Hill, Chapel Hill · 10 mi lwen
A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)
Ap rekriteFaz 2
- University of North Carolina at Chapel Hill, Chapel Hill · 10 mi lwen
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
Ap rekriteFaz 3
- Duke University Medical Center, Durham
- Duke Cancer Center Southpoint, Durham
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi lwen
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
Ap rekriteFaz 1
- Xencor Investigative Site, Durham
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
Ap rekriteFaz 1
- Duke Cancer Center /ID# 251975, Durham
A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body
Ap rekriteFaz 1/2
- University of North Carolina at Chapel Hill, Chapel Hill · 10 mi lwen
Etid Kansè renn (Kasinom selil renn) nan lòt vil
- Houston, TX35 etid
- New York City, NY27 etid
- Nashville, TN23 etid
- Dallas, TX23 etid
- St. Louis, MO23 etid
- Los Angeles, CA20 etid
- Boston, MA16 etid
- Baldwin Park, CA16 etid
- Philadelphia, PA15 etid
- Pittsburgh, PA15 etid
- Queens, NY15 etid
- Jacksonville, FL14 etid
Lòt etid nan Durham
- Kansè nan tete64 etid
- Kansè (tout kalite)58 etid
- Kansè Poumon ki pa ti selil39 etid
- Myelom Miltip37 etid
- Leksemi mieloïd egi33 etid
- Kansè Metastatik33 etid
- Kansè pwostat32 etid
- Kansè poumon32 etid
- Kansè kolorektal28 etid
- Kansè ovè27 etid
- Lukemi lenfositè kwonik27 etid
- Ensifizyans kadyak26 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.